COMPANY

Optimum Therapeutics, LLC

HQ: Carlsbad, CA source · optimumtx.com ↗ · West Coast

Past trials only

Also known as Optimum Therapeutics · 40 sources

Location: Carlsbad, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: bladder cancer Non-small Cell Lung Cancer pancreatic cancer alopecia Suramin Drug:Docetaxel Drug: Carboplatin

1Trials (company is sponsor)39NIH grants

Timeline

2010-08 Trial start Phase 2: Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT01038752	Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer	Phase 2	Terminated	2010-08	2012-11 (actual)

NIH awards 39

Annual award amounts. Total $12.2M.

Jul 18, 2017 NIH award 5R01CA163015-07 FY2017: $390,100 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Targeting multiple signaling source ↗
Jun 24, 2016 NIH award 4R01CA163015-06 FY2016: $390,100 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Targeting multiple signaling source ↗
Aug 10, 2015 NIH award 5R01CA158300-05 FY2015: $372,483 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Synergistic chemo-siRNA comb source ↗
Jun 17, 2015 NIH award 5R01CA163015-05 FY2015: $378,396 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Targeting multiple signaling source ↗
Sep 9, 2014 NIH award 5R01EB015253-04 FY2014: $302,686 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Capturing dynamic and inter-depen source ↗
Jul 9, 2014 NIH award 5R01CA158300-04 FY2014: $361,309 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Synergistic chemo-siRNA comb source ↗
Jul 7, 2014 NIH award 5R01GM100487-04 FY2014: $337,479 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Multiscale computational models f source ↗
May 14, 2014 NIH award 5R01CA163015-04 FY2014: supplement or administrative line (under $1,000); activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Targeting multiple signaling steps source ↗
Aug 19, 2013 NIH award 5R01EB015253-03 FY2013: $294,261 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Capturing dynamic and inter-depen source ↗
Jul 17, 2013 NIH award 5R01CA158300-03 FY2013: $350,134 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Synergistic chemo-siRNA comb source ↗
Jul 1, 2013 NIH award 5R01GM100487-03 FY2013: $325,667 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Multiscale computational models f source ↗
Mar 15, 2013 NIH award 5R01CA163015-03 FY2013: $366,694 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Targeting multiple signaling source ↗
Sep 21, 2012 NIH award 7R01CA163015-02 FY2012: $390,100 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Targeting multiple signaling source ↗
Sep 8, 2012 NIH award 1R43TR000356-01 FY2012: $344,460 awarded for that fiscal year; activity R43 (SBIR); PI LU, ZE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Combination chemo-siRNA gene therapy of nonmuscl source ↗
Aug 28, 2012 NIH award 5R43CA162448-02 FY2012: $105,157 awarded for that fiscal year; activity R43 (SBIR); PI LU, ZE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Intra-bladder MMC & suramin for nonmuscle-invadi source ↗
Aug 27, 2012 NIH award 7R01EB015253-02 FY2012: $297,956 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Capturing dynamic and inter-depen source ↗
Aug 2, 2012 NIH award 7R01GM100487-02 FY2012: $337,479 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Multiscale computational models f source ↗
Jul 19, 2012 NIH award 5R01CA158300-02 FY2012: $372,483 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Synergistic chemo-siRNA comb source ↗
Apr 23, 2012 NIH award 5R01CA077091-09 FY2012: $333,500 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Telomeres, telomerase and chemoth source ↗
Apr 5, 2012 NIH award 3R44CA103133-04S1 FY2012: $50,000 awarded for that fiscal year; activity R44 (SBIR); PI LU, ZE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Apoptosis Inducing to Enhance Tumor Targeting source ↗
Sep 26, 2011 NIH award 1R01CA158300-01 FY2011: $372,483 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIENTJES, M GUILLAUME; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Synergistic chemo-siRNA comb source ↗
Sep 22, 2011 NIH award 1R43CA162448-01 FY2011: $198,069 awarded for that fiscal year; activity R43 (SBIR); PI LU, ZE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Intra-bladder MMC & suramin for nonmuscle-invadi source ↗
Aug 18, 2011 NIH award 5R01CA077091-08 FY2011: supplement or administrative line (under $1,000); activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Telomeres, telomerase and chemotherapy: source ↗
Apr 27, 2010 NIH award 5R01CA077091-07 FY2010: $352,225 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Telomeres, telomerase and chemoth source ↗
Sep 29, 2009 NIH award 3R44CA107743-04S1 FY2009: $400,000 awarded for that fiscal year; activity R44 (SBIR); PI LU, ZE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Rapid release paclitaxel nanoparticles for bla source ↗
Aug 14, 2009 NIH award 5R44CA107743-04 FY2009: $645,019 awarded for that fiscal year; activity R44 (SBIR); PI LU, ZE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Rapid release paclitaxel nanoparticles for bladd source ↗
Aug 3, 2009 NIH award 5R43CA134047-02 FY2009: $125,561 awarded for that fiscal year; activity R43 (SBIR); PI WANG, JIE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Intraperitoneal Tumor-Targeting Chemo-gene Th source ↗
Apr 22, 2009 NIH award 5R01CA077091-06 FY2009: $346,857 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Telomeres, telomerase and chemoth source ↗
Sep 19, 2008 NIH award 2R44CA107743-03 FY2008: $730,684 awarded for that fiscal year; activity R44 (SBIR); PI LU, ZE; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Rapid release paclitaxel nanoparticles for bladd source ↗
Sep 17, 2008 NIH award 7R01CA077091-05 FY2008: $338,540 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AU, JESSIE L.-S.; recipient as written: OPTIMUM THERAPEUTICS, LLC, CARLSBAD, CA. Telomeres, telomerase and chemoth source ↗